summary: This study compared progression of disability in people with relapsing-remitting MS on beta-interferon with a control group from years ago who were not taking treatment. They reported that interferon delayed progression of disability over five years, although this was not a placebo controlled trial. They also found that the number of relapses in the early years predicted early relapse on beta-interferon treatment.

authors: Carmona O, Casado V, Moral E, Alonso-Magdalena L, Martínez-Yélamos A, Martínez-Yélamos S, Martín-Ozaeta G, Arbizu T

source: Eur Neurol. 2008 Sep 27;60(6):279-284 [Epub ahead of print]

weblink: click here

category: Epidemiology

related research news: click here

glossary: